2. INTRODUCTION
⢠It is obstructive pulmonary disease.
⢠Defined as chronic inflammatory disorder of
airways characterized by airway hyper
responsiveness and airflow obstruction leading
to recurrent episodes of coughing, wheezing,
breathlessness & chest tightnessâŚ
3. ETIOLOGY
1) Airway Hyperactivity
⢠It is tendency of airway to narrow in response to
triggers that have little or no effect in normal
individuals.
⢠Causes of airway hyperactivity
⢠Airway inflammation
⢠Degree of airway narrowing
⢠Neurogenic mechanisms
7. EARLY OR IMMEDIATE BRONCHO
CONSTRICTOR RESPONSE
⢠Occurs shortly after exposure to allergen within
first 15 min - 1hour.
⢠Caused by mediators of immediate
hypersensitivity reaction; mast cells/basophils,
release mediators and causes inflammation that
leads to airway hyperactivity.
8. LATE BRONCHO CONSTRICTOR RESPONSE
⢠Occurs late after exposure to allergen about
4-6 hours after.
⢠Caused by influx of inflammatory cells and
then releasing mediators which causes
inflammation which leads to airway
hyperactivity.
12. ⢠Daily,
Throughout
Day
⢠Asthma Attack
Daily
⢠Not Throughout
Day
⢠Greater Than 2
Days/Week
⢠Not Daily
⢠Asthma Attack
⢠Less Than 2
Days/Week
Intermittent
Mild
Persistent
Sever
Persistent
Moderate
Persistent
15. ⢠Clinical History
⢠Demonstration of airflow obstruction by using spirometry or peak flow
meter.
⢠If
⢠FEV âĽ15% increases after administration of
bronchodilator, Asthma is present.
⢠> 20% diurnal variation on ⼠3 days in week for
2 weeks on PEF, Asthma is present.
⢠FEV ⼠15% decrease after 6 min exercise,
Asthma is present.
16. OTHER INVESTIGATIONS
⢠Measurement of allergic status
⢠Presence of atopy by skin prick test
⢠Measurement of Ig E
⢠FBC, for eosinophilia
⢠Radiological exam
⢠CXR often normal or show hyperinflation of lung.
18. STEP 1
â˘Occasional use of inhaled
short acting B2 â adrenal
receptor agonist
bronchodilators
⢠E.g. Salbutamol, Terbutaline (in mild intermittent asthma)
20. STEP 3 (add on Therapy)
⢠Change short acting beta agonist with long acting beta
agonist(LABA).
Inhaled
Corticosteroids
Long Acting
Beta agonists
21. STEP 4 (Addition of 4th Drug)
⢠Used in those whose poor control on moderate dose of inhaled
corticosteroid & LABA.
⢠Discontinue the LABA from ICS and give any of following.
22. STEP 5
⢠continues use of oral steroids for control of symptoms
⢠Osteoporosis caused by corticosteroid can be prevented by
giving bisphosphonates.
⢠In atopic Patients, omalizumab (monoclonal antibody
directed against I g E.
⢠Note: once asthma is controlled slowly reduce dose of
corticosteroids.
24. Management of MILD to MODERATE Asthma
â˘Short course of rescue
oral corticosteroid
â˘(Prednisolone 30-60 mg
daily)
25. Management of STATUS ASTHAMATICUS
(Features)
â˘PEF = 33-50%
â˘Respiratory Rate ⼠25
breaths/minute
â˘Heart rate ⼠110 beats/minute
â˘Inability to complete sentence in
one breath
26. TREATMENT OF STATUS ASTHAMATICUS
⢠Oxygenation (O2 saturation should be > 92%)
⢠High dose inhaled bronchodilators
⢠SHORT ACTING B2 AGONIST ARE DRUG OF CHOICE
⢠Salbutamol
⢠Ipratropium bromide
⢠Systemic corticosteroids
⢠Orally; Prednisolone
⢠IV; Hydrocostisone
Still No
ResponseâŚ.
Go for
INTUBATION
27. Give me your precious feedback on
Twitter @hotchandaniss